Alembic Pharmaceuticals has informed the exchange that its Associate Company, Rhizen Pharmaceuticals SA (Rhizen) has released a Press Release announcing that it has entered into an exclusive license agreement with Curon Biopharmaceutical for development and commercialization of Tenalisib, a Dual Pl3K Delta and Gamma Inhibitor for Oncology in Greater China. It has enclosed Rhizen's press release. Alembic Pharmaceuticals through its wholly owned subsidiary holds 50% ownership in Rhizen.
The above information is a part of company’s filings submitted to BSE.
